Development and validation of donor adverse reaction severity grading tool: enhancing objective grade assignment to donor adverse events
BACKGROUND Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from A...
Saved in:
Published in | Transfusion (Philadelphia, Pa.) Vol. 60; no. 6; pp. 1231 - 1242 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.06.2020
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND
Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool.
STUDY DESIGN AND METHODS
Between January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter‐rater reliability was evaluated by Kendallʼs coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received.
RESULTS
The overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78‐0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs.
CONCLUSION
The development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV.
See editorial on page 1115–1117, in this issue |
---|---|
AbstractList | BACKGROUNDUniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool.STUDY DESIGN AND METHODSBetween January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter‐rater reliability was evaluated by Kendallʼs coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received.RESULTSThe overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78‐0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs.CONCLUSIONThe development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV. See editorial on page 1115–1117, in this issue Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well-recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool. Between January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter-rater reliability was evaluated by Kendall's coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received. The overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78-0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs. The development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV. BACKGROUND Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool. STUDY DESIGN AND METHODS Between January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter‐rater reliability was evaluated by Kendallʼs coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received. RESULTS The overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78‐0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs. CONCLUSION The development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV. See editorial on page 1115–1117, in this issue Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well-recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool.BACKGROUNDUniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well-recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool.Between January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter-rater reliability was evaluated by Kendall's coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received.STUDY DESIGN AND METHODSBetween January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter-rater reliability was evaluated by Kendall's coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received.The overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78-0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs.RESULTSThe overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78-0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs.The development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV.CONCLUSIONThe development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV. |
Author | Townsend, Mary Wiersum‐Osselton, Johanna Rosa‐Bray, Marilyn Gottschall, Jerome Rajbhandary, Srijana Van Buren, Nancy Kamel, Hany |
Author_xml | – sequence: 1 givenname: Mary orcidid: 0000-0001-7759-0676 surname: Townsend fullname: Townsend, Mary email: mtownsend@vitalant.org organization: Vitalant – sequence: 2 givenname: Hany surname: Kamel fullname: Kamel, Hany organization: Vitalant – sequence: 3 givenname: Nancy surname: Van Buren fullname: Van Buren, Nancy organization: Innovative Blood Resources – sequence: 4 givenname: Johanna orcidid: 0000-0003-3451-9911 surname: Wiersum‐Osselton fullname: Wiersum‐Osselton, Johanna organization: Sanquin Blood Bank – sequence: 5 givenname: Marilyn surname: Rosa‐Bray fullname: Rosa‐Bray, Marilyn organization: Biomat USA, Inc.–Grifols – sequence: 6 givenname: Jerome surname: Gottschall fullname: Gottschall, Jerome organization: Versiti Wisconsin – sequence: 7 givenname: Srijana surname: Rajbhandary fullname: Rajbhandary, Srijana organization: AABB |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32452048$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1OGzEURq2KqgTogheoLLEpiwH_znjYISgUCakSomvL8dwJjiZ2ajup8gY8ds0kbKLijWX5fMfW_Y7QgQ8eEDql5IKWdZljf0Gl4uQTmlDJm4q1rTxAE0IErSjl7BAdpTQnhLCW0C_okDMhGRFqgl5vYQ1DWC7AZ2x8h9dmcJ3JLngcetwFHyI23RpiAhzB2PEmlVB0eYNn0XTOz3AOYbjC4F-Mt2_nMJ1DQdcwEoBNSm7mx0dy2LMWl8_pBH3uzZDg624_Rr_vfjzf_Kwef90_3Fw_VpZLTiojVU96wplRXBBQtK8lZ60VgshaKSVoA01tjSS1rdsptZQqwQyXDWP91AI_Rt-33mUMf1aQsl64ZGEYjIewSpoJUreiOHlBz_bQeVhFX35XKMo5bdqaFerbjlpNF9DpZXQLEzf6fcYFuNwCNoaUIvTaujxOOEfjBk2JfmtRlxb12GJJnO8l3qX_Y3f2v26Azcegfn662yb-AeDzrEY |
CitedBy_id | crossref_primary_10_1016_j_tracli_2022_09_070 crossref_primary_10_1111_vox_13502 crossref_primary_10_1111_vox_13048 crossref_primary_10_1111_vox_13421 crossref_primary_10_1016_j_tmrv_2023_150777 crossref_primary_10_1186_s13063_024_08035_7 crossref_primary_10_1002_jca_22146 crossref_primary_10_1111_vox_13392 crossref_primary_10_1111_trf_15854 crossref_primary_10_1177_26348535231207051 crossref_primary_10_1111_trf_16668 crossref_primary_10_1016_j_tracli_2025_03_001 crossref_primary_10_1016_j_tmrv_2024_150851 crossref_primary_10_1111_trf_16333 crossref_primary_10_1111_trf_17862 crossref_primary_10_1111_trf_16572 |
Cites_doi | 10.1001/jama.299.19.2279 10.1111/j.1423-0410.2010.01442.x 10.1111/j.1537-2995.2011.03401.x 10.1111/trf.15133 10.1111/vox.12323 10.4135/9781412961288 10.1016/j.biologicals.2011.12.003 10.1111/j.1537-2995.2007.01163.x 10.1111/j.1423-0410.1998.tb05454.x 10.1136/bmj.331.7520.800-c 10.1111/trf.14948 10.1182/blood-2018-09-873125 10.1111/trf.14921 10.1111/j.1537-2995.2011.03074.x |
ContentType | Journal Article |
Copyright | 2020 AABB 2020 AABB. |
Copyright_xml | – notice: 2020 AABB – notice: 2020 AABB. |
DBID | AAYXX CITATION NPM 7QO 7U9 8FD FR3 H94 K9. P64 7X8 |
DOI | 10.1111/trf.15830 |
DatabaseName | CrossRef PubMed Biotechnology Research Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | Virology and AIDS Abstracts CrossRef PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-2995 |
EndPage | 1242 |
ExternalDocumentID | 32452048 10_1111_trf_15830 TRF15830 |
Genre | article Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 123 1OB 1OC 29Q 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBNA ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ H~9 IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SJN SUPJJ TEORI TWZ UB1 UCJ V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WUP WVDHM WXI WXSBR X7M XG1 YFH YQI YQJ YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX ABJNI AEYWJ AGHNM AGQPQ AGYGG CITATION NPM YIN 7QO 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 H94 K9. P64 7X8 |
ID | FETCH-LOGICAL-c3530-a58f0f032a8340e81f65329c44056888417e76ca506c69b1c11842a35722fbce3 |
IEDL.DBID | DR2 |
ISSN | 0041-1132 1537-2995 |
IngestDate | Fri Jul 11 10:52:51 EDT 2025 Wed Aug 13 06:58:38 EDT 2025 Wed Feb 19 02:29:49 EST 2025 Thu Apr 24 22:55:54 EDT 2025 Tue Jul 01 00:28:32 EDT 2025 Wed Jan 22 16:33:09 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
License | 2020 AABB. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3530-a58f0f032a8340e81f65329c44056888417e76ca506c69b1c11842a35722fbce3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0001-7759-0676 0000-0003-3451-9911 |
PMID | 32452048 |
PQID | 2413317962 |
PQPubID | 1096380 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2406945323 proquest_journals_2413317962 pubmed_primary_32452048 crossref_citationtrail_10_1111_trf_15830 crossref_primary_10_1111_trf_15830 wiley_primary_10_1111_trf_15830_TRF15830 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2020 |
PublicationDateYYYYMMDD | 2020-06-01 |
PublicationDate_xml | – month: 06 year: 2020 text: June 2020 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Bethesda |
PublicationTitle | Transfusion (Philadelphia, Pa.) |
PublicationTitleAlternate | Transfusion |
PublicationYear | 2020 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2005; 331 2010 2011; 51 2019; 59 2019 2016; 110 1998; 74 2008; 299 2019; 133 2011; 100 2007; 47 2012; 52 2018; 58 2012; 40 e_1_2_7_6_1 e_1_2_7_5_1 American Association of Blood Bank (AABB) (e_1_2_7_20_1) 2019 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_21_1 |
References_xml | – volume: 59 start-page: 1706 year: 2019 end-page: 16 article-title: Elevated risk for iron depletion in high‐school age blood donors publication-title: Transfusion – volume: 52 start-page: 702 year: 2012 end-page: 11 article-title: Iron deficiency in blood donors: the REDS‐II Donor Iron Status Evaluation (RISE) study publication-title: Transfusion – volume: 110 start-page: 185 year: 2016 end-page: 8 article-title: Development of standard definitions for surveillance of complications related to blood donation publication-title: Vox Sang – volume: 58 start-page: 2589 year: 2018 end-page: 95 article-title: International validation of harmonized definitions for complications of blood donations publication-title: Transfusion – volume: 299 start-page: 2297 year: 2008 end-page: 86 article-title: Adverse reactions to allogeneic whole blood donation by 16‐ and 17‐year‐olds publication-title: JAMA – volume: 100 start-page: 60 year: 2011 end-page: 7 article-title: Hemovigilance: an effective tool for improving transfusion practice publication-title: Vox Sang – volume: 51 start-page: 1511 year: 2011 end-page: 21 article-title: Interventions to reduce the vasovagal rate in young whole blood donors publication-title: Transfusion – volume: 47 start-page: 621 year: 2007 end-page: 8 article-title: A revised classification scheme for acute transfusion reactions publication-title: Transfusion – start-page: 19 year: 2019 – volume: 133 start-page: 605 year: 2019 end-page: 14 article-title: Plateletpheresis‐associated lymphopenia in frequent platelet donors publication-title: Blood – volume: 74 start-page: 441 issue: Suppl 2 year: 1998 end-page: 5 article-title: The French haemovigilance system publication-title: Vox Sang – volume: 331 start-page: 800 year: 2005 article-title: EU tightens rules on blood safety publication-title: BMJ – volume: 40 start-page: 176 year: 2012 end-page: 9 article-title: Donor vigilance: what are we doing about it? publication-title: Biologicals – volume: 58 start-page: 2861 year: 2018 end-page: 7 article-title: Ferritin testing to characterize and address iron deficiency in young donors publication-title: Transfusion – year: 2010 – ident: e_1_2_7_5_1 doi: 10.1001/jama.299.19.2279 – ident: e_1_2_7_16_1 – ident: e_1_2_7_4_1 doi: 10.1111/j.1423-0410.2010.01442.x – ident: e_1_2_7_8_1 doi: 10.1111/j.1537-2995.2011.03401.x – ident: e_1_2_7_9_1 doi: 10.1111/trf.15133 – ident: e_1_2_7_11_1 doi: 10.1111/vox.12323 – ident: e_1_2_7_19_1 – ident: e_1_2_7_18_1 doi: 10.4135/9781412961288 – ident: e_1_2_7_6_1 doi: 10.1016/j.biologicals.2011.12.003 – ident: e_1_2_7_14_1 doi: 10.1111/j.1537-2995.2007.01163.x – ident: e_1_2_7_2_1 doi: 10.1111/j.1423-0410.1998.tb05454.x – ident: e_1_2_7_3_1 doi: 10.1136/bmj.331.7520.800-c – ident: e_1_2_7_17_1 – ident: e_1_2_7_13_1 doi: 10.1111/trf.14948 – ident: e_1_2_7_21_1 doi: 10.1182/blood-2018-09-873125 – ident: e_1_2_7_10_1 doi: 10.1111/trf.14921 – ident: e_1_2_7_7_1 doi: 10.1111/j.1537-2995.2011.03074.x – ident: e_1_2_7_12_1 – start-page: 19 volume-title: Standard 5.4.3. year: 2019 ident: e_1_2_7_20_1 – ident: e_1_2_7_15_1 |
SSID | ssj0002901 |
Score | 2.4103339 |
Snippet | BACKGROUND
Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance... See editorial on page 1115–1117, in this issue Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well-recognized challenges for donor hemovigilance (DHV). While... BACKGROUNDUniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1231 |
SubjectTerms | Agreements Blood & organ donations Blood donors Blood transfusion Complications Confidence intervals Evaluation Reliability analysis Transfusion |
Title | Development and validation of donor adverse reaction severity grading tool: enhancing objective grade assignment to donor adverse events |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ftrf.15830 https://www.ncbi.nlm.nih.gov/pubmed/32452048 https://www.proquest.com/docview/2413317962 https://www.proquest.com/docview/2406945323 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB6tOKBeWqAPFihyUQ-9ZBXbeS2cUMUKIcEBgcQBKbIdB2hRgnazF34BP5sZO0mXl4R6S5TJy56xv_GMvwH4abg1qjDjoCT-y4iScnQZFkFKNKgFl4X0CbInyeF5dHQRXwxgr9sL4_kh-gU3sgw3XpOBKz1bMPJmWo54nEny1ylXiwDR6T_qKIoP-ugyD6iaessqRFk8_Z1P56IXAPMpXnUTzuQTXHaf6vNM_o7mjR6Z-2csjv_5LyvwsQWibN9rzioMbLUGy8dtqP0zPCykEzFVFQxV8sYXYGJ1yYq6qqdMUTnnmWWIPN3-CIbzrKVyeOxq6pLzWVPXt7vMVtfE64Hntf7jh1gnYRli95srl5GAos-e6silZl_gfHJw9vswaMs2BEbGMgxUnJVhGUqhMhmFNuMl9rsYmwixYYIOd8RTmyZUiiExyVhzgz5OJJSMUyFKbaz8CktVXdl1YCINU2F5gl6jiHRqlCC-e51kCEtjnmZD-NV1YG5aTnMqrXGbd74NtmzuWnYIO73onSfyeE1oq9OCvLXlWU6RR0RZ40QM4Ud_Ga2QQiuqsvWcZGgDMf6mHMI3rz39WyQFt3GgxI91OvD26_Oz04k72Hi_6CZ8ELQE4BaGtmCpmc7td8RJjd52BvEI30MNvw |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCaCFuh62XtttmzVhh52cWBJfmXYZRgWpF2TQ5ACvRSGLctZ1sAeEufSX7CfPVKy3eeAojcbpl8SKX0UqY8Ah4prlWRq4OTEf-lRUk6au5kTEg1qxmUmbYLsJBidesdn_lkHvjZ7YSw_RLvgRpZhxmsycFqQvmbl1Srvcz-S6LBvU0Vv41BNr8ijKEJo48vcoXrqNa8Q5fG0t96cje5AzJuI1Uw5w2dw3nyszTS56G-qtK8ub_E4PvZvnsPTGouyb1Z5XkBHFy9hZ1xH21_B32sZRSwpMoZaubA1mFiZs6wsyhVLqKLzWjMEn2aLBMOpVlNFPDZfmfx8VpXl8gvTxS-i9sDzMv1tR1kjoRnC98XcJCWg6K2nGn6p9Ws4Hf6YfR85deUGR0lfuk7iR7mbu1IkkfRcHfEcu14MlIfwMECf2-OhDgOqxhCoYJByhW6OJxLph0LkqdLyDWwVZaH3gYnQDYXmATqOwktDlQiivE-DCJGpz8OoC5-bHoxVTWtO1TWWcePeYMvGpmW78KkV_WO5PO4T6jVqENfmvI4p-IhAaxCILnxsL6MhUnQlKXS5IRnaQ4y_KbuwZ9WnfYuk-DaOlfixRgn-__p4Nh2ag7cPFz2AJ6PZ-CQ-OZr8fAe7glYEzDpRD7aq1Ua_R9hUpR-MdfwDrAsR2g |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hKqFeoE_Ydtu6qIdesortxMm2p6p0BS0ghEDigBQljr2loGS1m730F_Rnd8ZOUqCthLglyuRlz9jfeMbfALzT3Oi81OPAEv9lREk5hQ3LICEa1JLLUvoE2UO1exp9PYvPVuBjtxfG80P0C25kGW68JgOflfaakTdzO-JxKtFffxCpMCWV3jn-wx1FAUIfXuYBlVNvaYUojae_9eZk9BfCvAlY3Ywz2YDz7lt9osnlaNkUI_3zFo3jPX_mEay3SJR98qrzGFZM9QTWDtpY-1P4dS2fiOVVyVAnL3wFJlZbVtZVPWc51XNeGIbQ022QYDjRGqqHx6Zzl53Pmrq--sBM9Z2IPfC8Ln74MdZJGIbg_WLqUhJQ9NZTHbvU4hmcTr6cfN4N2roNgZaxDIM8Tm1oQynyVEahSbnFjhdjHSE4VOhxRzwxiaJaDEqrccE1OjmRyGWcCGELbeRzWK3qymwBE0mYCMMVuo0iKhKdCyK8L1SKuDTmSTqA910HZrolNafaGldZ59xgy2auZQew3YvOPJPHv4SGnRZkrTEvMgo9IswaKzGAt_1lNEOKreSVqZckQzuI8TflADa99vRvkRTdxpESP9bpwP9fn50cT9zBi7uLvoG1o51Jtr93-O0lPBS0HOAWiYaw2syX5hVipqZ47WzjN4eXEJI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+validation+of+donor+adverse+reaction+severity+grading+tool%3A+enhancing+objective+grade+assignment+to+donor+adverse+events&rft.jtitle=Transfusion+%28Philadelphia%2C+Pa.%29&rft.au=Townsend%2C+Mary&rft.au=Kamel%2C+Hany&rft.au=Van+Buren%2C+Nancy&rft.au=Wiersum%E2%80%90Osselton%2C+Johanna&rft.date=2020-06-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=0041-1132&rft.eissn=1537-2995&rft.volume=60&rft.issue=6&rft.spage=1231&rft.epage=1242&rft_id=info:doi/10.1111%2Ftrf.15830&rft.externalDBID=10.1111%252Ftrf.15830&rft.externalDocID=TRF15830 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-1132&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-1132&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-1132&client=summon |